Find clinical trials for multiple myeloma. Search for multiple myeloma clinical trials in different cities and states across the United States.
Filter
1
Filter results
Results: 1,134
Active & ResponsiveNew
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
for
Relapsed or Refractory Multiple Myeloma
Location: Nashville TN
Sponsor: ModernaTX, Inc.
Sex: All
Age: 18+
Code: NCT07116616
Phase1, Phase2, Recruiting
Active & ResponsiveNew
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: Birmingham AL, New Haven CT, Houston TX, Toronto
Sponsor: Celgene
Sex: All
Age: 18+
Code: NCT06988488
Phase1, Phase2, Recruiting
Active & ResponsiveNew
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
for
Multiple Myeloma
Location: San Diego CA, New Haven CT, Tampa FL, Indianapolis IN,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT04133636
Phase2, Recruiting
Active & Responsive
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: Birmingham AL, Phoenix AZ, Duarte CA, Jacksonville FL,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Sex: All
Age: 18+
Code: NCT06121843
Phase1, Recruiting
Active & Responsive
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
for
Relapsed or Refractory Multiple Myeloma (RRMM)
Location: Birmingham AL, Los Angeles CA, Atlanta GA,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Sex: All
Age: 18+
Code: NCT06615479
Phase3, Recruiting
Active & Responsive
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
for
Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer,
Location: Duarte CA, Miami FL, Gainesville GA, New Albany IN,